ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1605

Ckd.Qld fabRy Epidemiology (aCQuiRE) Study: Fabry Disease Prevalence Among Patients with CKD

Session Information

Category: Genetic Diseases of the Kidneys

  • 1002 Genetic Diseases of the Kidneys: Non-Cystic


  • Mallett, Andrew John, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
  • Kearey, Phoebe Jane, The University of Queensland Faculty of Medicine, Herston, Queensland, Australia
  • Cameron (Salisbury), Anne, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
  • Healy, Helen G., Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
  • Denaro, Charles P., Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
  • Thomas, Mark AB, Royal Perth Hospital, Perth, Western Australia, Australia
  • Lee, Vincent W.S., Westmead Hospital, Westmead, New South Wales, Australia
  • Fuller, Maria, Genetics and Molecular Pathology Laboratory, SA Pathology, Adelaide, South Australia, Australia
  • Hoy, Wendy E., The University of Queensland Faculty of Medicine, Herston, Queensland, Australia

Group or Team Name

  • aCQuiRE Study Team

Fabry disease (FD) is a rare, genetic disorder resulting in absence or deficiency of alpha-galactosidase A (α-Gal A), leading to accumulation of globotriaosylceramide (GB3) in cells and tissues. Associated mortality and morbidity are due to renal, cardiac, and cerebrovascular manifestations. General population prevalence is ~0.0025%. Dialysis population prevalence is estimated at 0.12-0.36%. Little is known about the prevalence of FD amongst wider chronic kidney disease (CKD) populations. Although FD is X-linked, affected females can have variable disease manifestations. Prevalence amongst women is unclear.


A prospective cross-sectional study of FD prevalence amongst CKD patients in public Queensland nephrology services was undertaken across 7 sites Oct 2017-Aug 2019. Patients with all stages of CKD including Stage 5D/5T were eligible to participate, irrespective of prior CKD aetiology or diagnosis.3,000 CKD patients were screened using dried blood spot (DBS) testing. Repeat DBS and/or Lyso-GB3 testing was employed where results were inconclusive. FD was confirmed through diagnostic GLA genetic sequencing. All biochemical and genetic testing was undertaken in an accredited clinical laboratory.


6 unrelated cases (0.20%) of FD were identified. 3 were patients with a previously identified diagnosis of FD (100% sensitivity). 3 were patients with a new diagnosis of FD as a result of study participation. Of these 6 identified cases, 5/6 were male and 1/6 was female. This represented 0.3% and 0.08% of all male and female participants respectively. All newly diagnosed cases were male with two being CKD Stage 5T, and one being CKD Stage 5D. One case was in a participant who identified as Indigenous, the first known case in this population. In total, an additional 28 at-risk family members were identified who may benefit from family screening. No readily identifiable pattern of symptoms was identified.


Our results support the potential feasibility and utility of a cascade testing strategy principally using DBS, as a primary screening method for FD in adult patients with CKD. Further, we confirm that a significant proportion of prevalent cases of FD amongst those with CKD remains undiagnosed.


  • Commercial Support